Immix Biopharma, Inc. Common Stock IMMX

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

• GlobeNewswire Inc. 4 ago

  INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

  Pomerantz Law Firm is investigating Immix Biopharma for potential securities fraud after discovering that its newly appointed Chief Medical Officer, Richard Graydon, was actually Ronald L. Fischer, a fugitive wanted for a 2005 rape charge who had evaded authorities for over 20 years. Following the revelation, Immix's stock price dropped 14.15% on July 20, 2026.

  

• GlobeNewswire Inc. 24 jul

  EQPT LAWSUIT: EquipmentShare.com Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton To Learn How They Might Recover Their Losses

  EquipmentShare.com Inc. (EQPT) faces a securities fraud lawsuit after allegedly making false statements about terminating related-party transactions with founder-controlled entities. A short-seller report revealed undisclosed transactions netting founders at least $77 million, causing the stock to plummet 34.5% below its IPO price. Investors who purchased shares between January 23 and June 23, 2026, may be eligible to recover losses.

  

• GlobeNewswire Inc. 21 jul

  Immix Biopharma Investigated by the Portnoy Law Firm

  The Portnoy Law Firm has launched an investigation into possible securities fraud at Immix Biopharma after discovering that an executive operating under the alias 'Richard Graydon' was actually Ronald Fischer, a fugitive wanted in Rhode Island. The company terminated the officer on July 17, 2026, claiming the separation was unrelated to his activities. Following the disclosure, Immix's stock price declined approximately 10.83%.

  

• GlobeNewswire Inc. 20 jul

  IMMX ALERT: Immix Biopharma Investigated for Securities Fraud Violations by Block & Leviton; Investors Should Contact the Firm

  Block & Leviton is investigating Immix Biopharma for potential securities law violations after discovering that an executive operating under the name 'Richard Graydon' was actually a Rhode Island fugitive named Ronald Fischer using a false identity. The company terminated the individual on July 17, 2026, stating it was unrelated to his work activities. Immix shares fell approximately 10.83% following the news report.